QUASAR Life Sciences Consulting: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
QUASAR Life Sciences Consulting
Largest movements
- Cash +€69,701
up €69,701 (+140%), from €49,710 to €119,411
mainly Net result for the year (+€63,503) and Receivables within one year (+€8,208)
- Receivables within one year -€8,208
down €8,208 (-32.1%), from €25,549 to €17,341
of which Trade receivables: -€11,973
- Profit (loss) carried forward +€63,503
up €63,503 (+137%), from €46,493 to €109,996
- Gross operating margin +€27,326
up €27,326 (+46.7%), from €58,521 to €85,847
- Taxes +€6,588
up €6,588 (+55.4%), from €11,882 to €18,469
- Financial charges +€2,207
up €2,207 (+2,318%), from €95 to €2,302
- Other operating charges +€1,406
new in 2025: €1,406
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €76,853 | €139,413 | +€62,560 | +81.4% |
| Fixed assets | 21/28 | €1,594 | €1,428 | -€166 | -10.4% |
| Tangible fixed assets | 22/27 | €1,594 | €1,428 | -€166 | -10.4% |
| Plant, machinery and equipment | 23 | €1,594 | €1,428 | -€166 | -10.4% |
| Current assets | 29/58 | €75,259 | €137,985 | +€62,726 | +83.3% |
| Amounts receivable within one year | 40/41 | €25,549 | €17,341 | -€8,208 | -32.1% |
| Trade receivables | 40 | €25,549 | €13,577 | -€11,973 | -46.9% |
| Other amounts receivable | 41 | - | €3,764 | +€3,764 | |
| Cash at bank and in hand | 54/58 | €49,710 | €119,411 | +€69,701 | +140% |
| Deferred charges and accrued income | 490/1 | - | €1,234 | +€1,234 | |
| Total equity and liabilities | 10/49 | €76,853 | €139,413 | +€62,560 | +81.4% |
| Equity | 10/15 | €48,493 | €111,996 | +€63,503 | +131% |
| Contributions | 10/11 | €2,000 | €2,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €46,493 | €109,996 | +€63,503 | +137% |
| Amounts payable | 17/49 | €28,360 | €27,417 | -€943 | -3.3% |
| Amounts payable within one year | 42/48 | €27,360 | €26,417 | -€943 | -3.4% |
| Trade debts | 44 | €131 | €307 | +€176 | +134% |
| Suppliers | 440/4 | €131 | €307 | +€176 | +134% |
| Taxes, remuneration and social security | 45 | €25,850 | €26,110 | +€260 | +1.0% |
| Taxes | 450/3 | €24,000 | €26,110 | +€2,110 | +8.8% |
| Remuneration and social security | 454/9 | €1,850 | - | -€1,850 | |
| Other amounts payable | 47/48 | €1,379 | - | -€1,379 | |
| Accrued charges and deferred income | 492/3 | €1,000 | €1,000 | = | 0.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €66 | €166 | +€100 | +151% |
| Other operating charges | 640/8 | - | €1,406 | +€1,406 | |
| Gross operating margin | 9900 | €58,521 | €85,847 | +€27,326 | +46.7% |
| Operating profit (loss) | 9901 | €58,455 | €84,274 | +€25,820 | +44.2% |
| Financial income | 75/76B | €15 | - | -€15 | |
| Recurring financial income | 75 | €15 | - | -€15 | |
| Financial charges | 65/66B | €95 | €2,302 | +€2,207 | +2,318% |
| Recurring financial charges | 65 | €95 | €2,302 | +€2,207 | +2,318% |
| Profit (loss) for the period before taxes | 9903 | €58,374 | €81,972 | +€23,598 | +40.4% |
| Income taxes | 67/77 | €11,882 | €18,469 | +€6,588 | +55.4% |
| Profit (loss) for the period | 9904 | €46,493 | €63,503 | +€17,010 | +36.6% |
| Profit (loss) for the period to be appropriated | 9905 | €46,493 | €63,503 | +€17,010 | +36.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 October 2026 via checked.be.